Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates

Teva is looking to tap into $6.5bn in US sales of Herceptin and Rituxan in a new deal for North American rights to two of Celltrion's pipeline biosimilars for $160m upfront.